Sio Capital Management, LLC Savara Inc Transaction History

Sio Capital Management, LLC

$266 Million
Q1 2025

A detailed history of Sio Capital Management, LLC transactions in Savara Inc stock. As of the latest transaction made, Sio Capital Management, LLC holds 719,654 shares of SVRA stock, worth $1.9 Million. This represents 0.75% of its overall portfolio holdings.

Number of Shares

719,654

Previous 3,747 19106.14%

Holding current value

$1.9 Million

Previous $11,000 18018.18%

% of portfolio

0.75%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$2.32 - $3.14 $1.66 Million - $2.25 Million	715,907 Added 19106.14%	719,654 $1.99 Million
Q4 2024 Feb 14, 2025	BUY	$2.94 - $4.07 $11,016 - $15,250	3,747 New	3,747 $11,000
Q3 2023 Nov 14, 2023	SELL	$2.97 - $3.88 $339,919 - $444,069	-114,451 Reduced 11.32%	896,250 $3.39 Million
Q2 2023 Aug 14, 2023	BUY	$1.69 - $3.24 $105,192 - $201,670	62,244 Added 6.56%	1,010,701 $3.22 Million
Q1 2023 May 12, 2023	BUY	$1.6 - $2.82 $131,214 - $231,265	82,009 Added 9.46%	948,457 $1.85 Million
Q4 2022 Feb 13, 2023	BUY	$1.11 - $1.64 $11,122 - $16,432	10,020 Added 1.17%	866,448 $1.34 Million
Q2 2022 Aug 15, 2022	BUY	$1.1 - $1.58 $154,182 - $221,462	140,166 Added 19.57%	856,428 $1.3 Million
Q1 2022 May 16, 2022	BUY	$1.05 - $1.36 $68,346 - $88,525	65,092 Added 10.0%	716,262 $938,000
Q4 2021 Feb 14, 2022	BUY	$1.04 - $1.34 $677,216 - $872,567	651,170 New	651,170 $807,000
Q3 2019 Nov 14, 2019	SELL	$2.16 - $3.2 $864,000 - $1.28 Million	-400,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.37 - $11.7 $948,000 - $4.68 Million	400,000 New	400,000 $948,000

Others Institutions Holding SVRA

# of Institutions

140

Shares Held

162M

Call Options Held

54.8K

Put Options Held

4.1K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $301M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sio Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sio Capital Management, LLC with notifications on news.

Account

Sio Capital Management, LLC Savara Inc Transaction History